Kaiting Yang

Cooley advised the underwriters of Duality Biologics (DualityBio), a clinical-stage biotech company focused on the discovery and development of next-generation antibody-drug conjugate therapeutics for patients with cancer and autoimmune diseases, in connection with its HK$1.64 billion global initial public offering (IPO).

Cooley advised the sponsors and underwriters of Jiangsu Zenergy Battery Technologies Group (Zenergy) – a lithium-ion battery manufacturer focusing on the research and development, production and sales of electric vehicle battery products, electrochemical energy storage battery products and aviation battery products – in connection with Zenergy’s HK$1 billion global initial public offering.

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Harbour BioMed (HBM Holdings, HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in oncology and immunology, on its share subscription agreement with AstraZeneca.

Cooley advised the sponsors and underwriters of BrainAurora Medical Technology, a provider of medical diagnostics and digital therapies, in connection with the company’s HK$583 million initial public offering.